Although our current study is limited to FSHD2 primary myocytes from tibialis anterior, our strategy should be effective in further analyzing FSHD pathophysiology during different stages of muscle differentiation and in biopsies and muscle types with different sensitivities to the disease at a single nucleus resolution. This evidence concerns the gene SMCHD1 and facioscapulohumeral muscular dystrophy.